Smartinhaler maker Adherium has announced the appointment of former MicroDose Therapeutx co-founder Scott Fleming as Senior VP of Business Development, Europe, effective immediately. Fleming replaces John Tarplee who left the company at the end of 2016 "to pursue a new venture." After the sale of MicroDose Therapeutx to Teva in 2013, Fleming served as Senior … [Read more...] about Adherium appoints Scott Fleming as Senior VP of Business Development, Europe
People
Nanopharm appoints Arron Danson as Head of Device Development
OINDP development specialist Nanopharm has appointed Arron Danson as Head of Device Development, the company said. Danson has extensive experience in the development of pulmonary and nasal delivery devices, having worked at companies such as Vectura, Coalesce Product Development, and, most recently, Kinneir Dufort. Nanopharm, which announced the appointment of … [Read more...] about Nanopharm appoints Arron Danson as Head of Device Development
Avanir appoints Richard Malamut Senior VP of R&D, CMO
Avanir Pharmaceuticals, which launched its Onzetra Xsail intranasal dry powder sumatriptan in the US in May 2016, has announced the appointment of Richard Malamut as Senior VP, Research and Development and Chief Medical Officer. Malamut was most recently Senior VP of Global Clinical Development and Head of Pain, Oncology, Neuropsychiatry and NTEs at Teva … [Read more...] about Avanir appoints Richard Malamut Senior VP of R&D, CMO
Savara Pharmaceuticals appoints David L. Lowrance as CFO
Inhaled drug developer Savara Pharmaceuticals has announced the appointment of former Edgemont Pharmaceuticals CFO David L. Lowrance as its new Chief Financial Officer. Savara cited Lowrance's experience leading IPOs for Acucela, where he was CFO and Secretary, and Cumberland Pharmaceuticals, where he was VP and CFO. Savara Chairman and CEO Rob Neville commented, … [Read more...] about Savara Pharmaceuticals appoints David L. Lowrance as CFO
OptiNose appoints Tom Gibbs as Chief Commercial Officer
OptiNose has appointed Tom Gibbs as Chief Commercial Officer to oversee the commercialization strategy for EDS-FLU (OPN-375) intranasal fluticasone, which is in Phase 3 development for the treatment of nasal congestion in patients with nasal polyposis. Gibbs was most recently Senior VP and Head of the General Medicines Business Unit, US for Takeda. Gibbs said, “I … [Read more...] about OptiNose appoints Tom Gibbs as Chief Commercial Officer
Insmed appoints Roger Adsett as Chief Commercial Officer
Insmed has appointed Roger Adsett, a former global brand director for Symbicort, as its new Chief Commercial Officer in preparation for commercialization of Arikayce inhaled liposomal amikacin. Adsett also spent a portion of his time with AstraZeneca overseeing global marketing strategy for Rhinocort and Rhinocort Aqua. He was most recently Senior VP, Head of … [Read more...] about Insmed appoints Roger Adsett as Chief Commercial Officer
Nanopharm appoints Mark Clement as Chairman of the Board
OINDP developer Nanopharm has announced the appointment of Mark Clement as non-executive Chairman of the Board. Clement has more than 25 years of experience in life sciences and is currently non-executive chairman or director of 6 companies in the industry. Nanopharm co-Founder and Director Rob Price said, "Mark’s extensive experience in managing Life Science … [Read more...] about Nanopharm appoints Mark Clement as Chairman of the Board
Adherium announces management changes
Smartinhaler developer Adherium Limited has announced that Thomas Lynch has been appointed the company's new Chairman and that Doug Wilson will step down from the board to take on the role of Medical Director on a part time basis. Lynch recently retired from his role as Chair of ICON after serving on that company's board for over 20 years. He currently serves as … [Read more...] about Adherium announces management changes
Spyryx Biosciences appoints Alistair Wheeler as Chief Medical Officer
Spyryx Biosciences, which is developing an inhaled peptide for the treatment of cystic fibrosis and other respiratory diseases, has announced the appointment of former Sunovion Head of Clinical Research Alistair Wheeler as Chief Medical Officer, a newly created position. Spyryx's SPX-101 is currently in Phase 1 development for the treatment of cystic fibrosis. … [Read more...] about Spyryx Biosciences appoints Alistair Wheeler as Chief Medical Officer
Anna Slater joins PrEP Biopharm as Head of CMC
Johnson & Johnson spinout PrEP Biopharm has announced that former GSK Global Head of Analytical Technologies Anna Slater has joined the company as Head of Chemistry, Manufacturing and Controls. At GSK, Slater had been a Senior Director in the global Inhaled Product & Device Technology Leadership Team, responsible for CMC development of inhaled and nasal products and … [Read more...] about Anna Slater joins PrEP Biopharm as Head of CMC